AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02147925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin combined with metformin
Description: The dose throughout the study will be 100mg per day.
Study NCT03226522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: AXS-05
Study NCT03226522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion
Study NCT03226522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03958422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cardiomyopeptidin
Description: The main component of cardiomyopeptidin is the peptide active substance extracted from the ventricular myocytes of healthy young pigs.
Study NCT03616990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TASC Service Linkages - Discharge Area Only
Description: Individuals will meet with TASC Care Coordinators in the discharge area of the Cook County Jail. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.
Study NCT03616990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TASC Service Linkages - Discharge Area Only
Description: Individuals will meet with TASC Care Coordinators in the discharge area of the Cook County Jail. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.
Study NCT03616990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SRC Overnight Stay
Description: Individuals receiving SRC services will have the option to stay at the SRC overnight. At the SRC, individuals will be able to rest, have a meal, receive a change of clothes, and take a shower in a therapeutic, non-coercive environment.
Study NCT03616990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TASC Services Linkages - SRC Onsite
Description: While at the SRC, individuals will meet with TASC Care Coordinators. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.
Study NCT03616990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APN Appointment
Description: Individuals at the SRC will be able to meet with an Advanced Practice Nurse. As part of that visit, the APN will be able to prescribe medications or reroute prescriptions previously administered by the Cook County Jail's hospital, Cermak, to a participant's desired location as needed.
Study NCT01066182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA (docosahexaenoic acid)
Description: 3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
Study NCT01066182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil capsules
Description: The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
Study NCT01866319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 10 mg/kg IV, administered Q2W or Q3W based upon randomization.
Study NCT01866319 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 10 mg/kg IV, administered Q2W or Q3W based upon randomization.
Study NCT01866319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg IV Q3W.
Study NCT04192006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Surgical implantation of prosthetic knee using robotic-arm assist
Study NCT04192006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Surgical implantation of prosthetic knee using robotic-arm assist
Study NCT02972047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing
Description: Subjects in this are practice diaphragmatic breathing for 30 minutes after each meal.
Study NCT02972047 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Sham therapy (listening to music/watching TV for 30 minutes after each meal
Study NCT01482377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5479599
Description: RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).
Study NCT01482377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered via intravenous (IV) infusion at a starting dose of 400 mg/m\^2 for the first infusion, followed by doses of 250 mg/m\^2 for subsequent infusions.
Study NCT01482377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib, at a dose of 150 mg will be administered.
Study NCT01482377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zirconium-89-labeled RO5479599
Description: Single dose of radiolabeled drug will be administered.
Study NCT00886275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The loading dose of dexmedetomidine is 0.5 mcg/kg over 10 minutes as needed. Then, continuous infusion of 0.2-0.7 mcg/kg/h dexmedetomidine is used to maintain RASS between 0 to -3.
Study NCT00886275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: The loading dose of midazolam is 0.05 mg/kg over 10 minutes as needed. Then, continuous infusion of 20-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
Study NCT00886275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, Midazolam
Description: The loading doses are dexmedetomidine 0.25 mcg/kg and 0.025 mg/kg of midazolam over 10 minutes. Then, continuous infusion of 0.1-0.7 mcg/kg/h dexmedetomidine and 10-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
Study NCT01805583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Study NCT01805583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: workplace intervention (WPI)
Study NCT01759940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 0,375%
Study NCT01759940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine 0,75%
Study NCT01900080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same-Day HIV testing and ART initiation
Description: Same-day HIV testing and ART initiation
Study NCT01900080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ART Initiation
Description: Standard ART Initiation
Study NCT01900080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-Study: Same-Day ART, CD4 Count >500
Description: Same-day CD4 count and ART initiation for patients with CD4 count >500 cells/mm3 (CD4 count within 7 days of HIV test)
Study NCT01900080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Study: Standard Pre-ART Care, CD4 Count >500
Description: Standard pre-ART care for patients with CD4 count >500 cells/mm3
Study NCT00388544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity matched to interest
Description: Recreational activities are tailored to subject's style of interest
Study NCT00388544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity matched to function
Description: Recreational activities are tailored to subjects physical and cognitive functioning
Study NCT00388544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity matched to both interest and function
Description: Recreational activities are tailored to both style of interest and physical and cognitive functioning.
Study NCT04000100 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound- guided supraclavicular brachial plexus block
Description: Patient lie down supine with head turned 45 degrees to the contralateral side and ipsilateral arm adducted gently by the assistant and the shoulder kept down with flexed elbow.~After sterile preparation of the skin and the ultrasound probe (12 MHz probe) were used, the brachial plexus was visualized by placing the transducer in the sagittal plane in the supraclavicular fossa behind the middle-third of the clavicle. Two distinct appearances of the brachial plexus was seen at the supraclavicular region, it either appeared as 3 hypoechoic circles with hyperechoic outer rings or as a grape like cluster of 5 to 6 hypoechoic circles, located lateral and superior to the subclavian artery between the anterior and middle scalene muscles at the lower cervical region figure
Study NCT04000100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound- guided supraclavicular brachial plexus block
Description: Patient lie down supine with head turned 45 degrees to the contralateral side and ipsilateral arm adducted gently by the assistant and the shoulder kept down with flexed elbow.~After sterile preparation of the skin and the ultrasound probe (12 MHz probe) were used, the brachial plexus was visualized by placing the transducer in the sagittal plane in the supraclavicular fossa behind the middle-third of the clavicle. Two distinct appearances of the brachial plexus was seen at the supraclavicular region, it either appeared as 3 hypoechoic circles with hyperechoic outer rings or as a grape like cluster of 5 to 6 hypoechoic circles, located lateral and superior to the subclavian artery between the anterior and middle scalene muscles at the lower cervical region figure
Study NCT04828720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ozonated oil
Description: All patients in ozone group were asked to visit the clinic on a daily basis through the first week and have their allocated therapeutic medication applied to their particular palatal donor site wounds. The wounds were coated with 2 ml ozonated oil per day, with a concentration of 15 µg of ozone/ml of olive oil. Moreover, palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in ozone group used a soft stent to protect the palatal donor wound site and to retain the tested oils in the post harvested palatal wounds. Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
Study NCT04828720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ozonated oil
Description: All patients in ozone group were asked to visit the clinic on a daily basis through the first week and have their allocated therapeutic medication applied to their particular palatal donor site wounds. The wounds were coated with 2 ml ozonated oil per day, with a concentration of 15 µg of ozone/ml of olive oil. Moreover, palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in ozone group used a soft stent to protect the palatal donor wound site and to retain the tested oils in the post harvested palatal wounds. Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
Study NCT04828720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozonated oil
Description: All patients in ozone group were asked to visit the clinic on a daily basis through the first week and have their allocated therapeutic medication applied to their particular palatal donor site wounds. The wounds were coated with 2 ml ozonated oil per day, with a concentration of 15 µg of ozone/ml of olive oil. Moreover, palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in ozone group used a soft stent to protect the palatal donor wound site and to retain the tested oils in the post harvested palatal wounds. Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
Study NCT02489422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02489422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02489422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02489422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02489422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily Survey Administration
Description: Ancillary studies
Study NCT02489422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily Survey Administration
Description: Ancillary studies
Study NCT02489422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Skills Training
Description: The YST intervention consists of four 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation. Participants will also be encouraged to practice daily at home.
Study NCT02489422 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The AC intervention consists of four 30 minute in-person sessions of supportive conversation. In addition, the interventionist will recommend that the patients write brief diary entries daily at home.
Study NCT02489422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actigraphy Assessment
Description: Ancillary studies
Study NCT02489422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Actigraphy Assessment
Description: Ancillary studies
Study NCT03726398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opsumit 10 Mg Tablet
Description: Oral tablet taken once daily
Study NCT00627575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamotrigine
Description: Lamotrigine tablets will be available in 25, 50, 100 and 200 mg dose strength.
Study NCT00627575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Atorvastatin will available as 40 mg tablets.
Study NCT00627575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenytoin
Description: Phenytoin will available as 100 mg capsules.
Study NCT04883723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shotblocker
Description: Shotblocker is a small, flat, horseshoe-shaped plastic tool that can be used to reduce pain due to intramuscular injection, suitable for all age groups, without drug properties. It is used by keeping it on the skin surface during injection and has no side effects. Shotblocker has short, non-pointed blunt protrusions on one side that connect with the skin, there is a hole in the middle of the vehicle to expose the injection site. The protruding surface of the vehicle is placed in the area to be applied just before injection. The protrusions on the surface of the Shotblocker do not pierce the skin and provide a warning for the Door Control Theory, which is thought to exist regarding pain
Study NCT04883723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Pressure
Description: The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated. There are many studies in the literature that prove the effectiveness of this method.
Study NCT02849353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance
Study NCT02849353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance
Study NCT02849353 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study NCT02772289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchyme Stem Cells low-dose group
Description: Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
Study NCT02772289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchyme Stem Cells high-dose group
Description: Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
Study NCT01024725 — intervention group
Intervention type: OTHER
Intervention: Follow-up
Description: Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
Study NCT03964558 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [14C]-acebilustat solution
Description: Acebilustat is a novel synthetic small molecule leukotriene A4 hydrolase (LTA4H) inhibitor.
Study NCT02772289 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
Study NCT00746798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 vaccine
Description: low dose, approximately 4 x 3log10, given one time subcutaneously
Study NCT00746798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 vaccine
Description: medium dose, approximately 4 x 4log10, given one time
Study NCT00746798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 vaccine
Description: high dose, approximately 4 x 5log10, given one time subcutaneously
Study NCT02358356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: octreotate
Description: 7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
Study NCT02358356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotate
Description: 7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
Study NCT02358356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: oral capecitabine 750mg/m2 b.i.d.
Study NCT02358356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral capecitabine 750mg/m2 b.i.d.
Study NCT02358356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: temozolomide 75mg/m2 b.i.d.
Study NCT02358356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide 75mg/m2 b.i.d.
Study NCT00201162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy
Description: Dietary supplement of isolated soy protein containing isoflavones
Study NCT00201162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dietary supplement casein placebo
Study NCT00158132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol 100mg/day in 3 divided doses
Study NCT00158132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Amantadine 100mg three times daily
Study NCT00158132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills
Study NCT01479426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EFLA400
Description: EFLA400(960mg/day)for 12 weeks
Study NCT01479426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo(960mg/day) for 12 weeks
Study NCT02545543 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seqirus QIV
Description: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.